b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29794429</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>10</Month>\n            <Day>22</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>10</Month>\n            <Day>22</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1423-0143</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>43</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Kidney &amp; blood pressure research</Title>\n                <ISOAbbreviation>Kidney Blood Press. Res.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Serum Fas Ligand, Serum Myostatin and Urine TGF-\xce\xb21 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>744-754</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000489911</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">The pathophysiology of renal disease progression in autosomal dominant polycystic disease (ADPKD) is largely unknown. Recent evidence suggests microvascular dysfunction leading to renal ischemia, as an additional pathway for renal function decline. This study examined the levels of serum Fas ligand (FasL), serum myostatin and urine transforming growth factor-beta 1 (TGF-\xce\xb21) and their association with markers of endothelial dysfunction, in ADPKD patients with preserved or impaired renal function.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">Seventy-eight participants were enrolled in the study, divided in three groups: Group A consisted of 26 ADPKD patients with impaired renal function (eGFR 45-70 ml/min/1.73m2), Group B of 26 ADPKD patients with preserved renal function (eGFR &gt; 70 ml/min/1.73m2), and Group C of 26 age- and sex- matched controls with no history of renal disease. Serum FasL, myostatin and urine levels of TGF-\xce\xb21 were measured as biomarkers of vascular dysfunction, apoptosis and fibrosis with ELISA techniques.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Group A patients had significantly higher levels of FasL (13.12\xc2\xb11.69 ng/mL), myostatin (4.62\xc2\xb10.59 ng/mL) and urine logTGF-\xce\xb21 (3.56\xc2\xb10.49 ng/24h) compared to Group B (9.6\xc2\xb11.28 ng/mL, 3.06\xc2\xb10.35, and 2.09\xc2\xb10.37, respectively, p&lt; 0.001 for all comparisons) or controls (6.59\xc2\xb11.17 ng/mL, 2.18\xc2\xb10.45 ng/ml, and 1.58\xc2\xb10.21, respectively, p&lt; 0.001 for all comparisons). Patients in Group B had also higher levels of all markers compared to controls (p&lt; 0.001), despite having similar renal function. In ADKPD patients negative associations of eGFR with FasL (r=-0.799, p&lt; 0.001), myostatin (r=-0.856, p&lt; 0.001) and TGF-\xce\xb21 (r=-0.476, p&lt; 0.001) but positive correlations of these markers with asymmetric dimethylarginine (ADMA) (r=0.825; r=0.749; and r=0.599, respectively p&lt; 0.001) were noted. Multivariate analysis demonstrated that FasL was independently associated with high urine TGF-\xce\xb21 (OR 3.774, 95%CI 1.180-12.072, p=0.025).</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ADPKD patients with moderately preserved renal function have higher levels of FasL, myostatin and urine TGF-\xce\xb21 than controls. These results indicate that an interplay between endothelial dysfunction and renal ischemia with mechanisms linked to apoptosis and fibrosis may be present even in early stages of ADPKD.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2018 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Raptis</LastName>\n                    <ForeName>Vassilios</ForeName>\n                    <Initials>V</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bakogiannis</LastName>\n                    <ForeName>Constantinos</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>3rd Department of Cardiology Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Loutradis</LastName>\n                    <ForeName>Charalampos</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Boutou</LastName>\n                    <ForeName>Afroditi K</ForeName>\n                    <Initials>AK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Respiratory Medicine, Papanikolaou Hospital, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sioulis</LastName>\n                    <ForeName>Athanasios</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Balaskas</LastName>\n                    <ForeName>Elias</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zebekakis</LastName>\n                    <ForeName>Pantelis</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sarafidis</LastName>\n                    <ForeName>Pantelis A</ForeName>\n                    <Initials>PA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Switzerland</Country>\n            <MedlineTA>Kidney Blood Press Res</MedlineTA>\n            <NlmUniqueID>9610505</NlmUniqueID>\n            <ISSNLinking>1420-4096</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C505661">FASLG protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C525911">MSTN protein, human</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D055435">Myostatin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005355" MajorTopicYN="N">Fibrosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005919" MajorTopicYN="Y">Glomerular Filtration Rate</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055435" MajorTopicYN="N">Myostatin</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016891" MajorTopicYN="N">Polycystic Kidney, Autosomal Dominant</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>\n                <QualifierName UI="Q000652" MajorTopicYN="Y">urine</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Apoptosis</Keyword>\n            <Keyword MajorTopicYN="N">Chronic kidney disease</Keyword>\n            <Keyword MajorTopicYN="N">Endothelial dysfunction</Keyword>\n            <Keyword MajorTopicYN="N">Fibrosis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>03</Month>\n                <Day>21</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>05</Month>\n                <Day>09</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29794429</ArticleId>\n            <ArticleId IdType="pii">000489911</ArticleId>\n            <ArticleId IdType="doi">10.1159/000489911</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'